Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis
07:30pm, Wednesday, 14'th May 2025
Explore the exciting world of Axsome Therapeutics (AXSM -1.70%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
07:00am, Tuesday, 13'th May 2025
Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervo
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years
07:08am, Monday, 12'th May 2025
Regardless of how stocks are performing right now, history tells us that the market tends to generate solid returns over long periods. Investors can do even better than the average market performance
3 Monster Stocks in the Making
11:15am, Sunday, 11'th May 2025
Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years.
Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns
12:48pm, Tuesday, 06'th May 2025
Axsome Therapeutics reported strong Q1 2025 earnings, with revenue and EPS beats driven by Auvelity and Sunosi, despite high SG&A expenses and net loss. Auvelity shows promising growth in the competit
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
10:41am, Tuesday, 06'th May 2025
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript
11:44am, Monday, 05'th May 2025
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Piz
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1
10:41am, Monday, 05'th May 2025
Axsome Therapeutics Inc AXSM on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million.
Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
10:35am, Monday, 05'th May 2025
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
09:15am, Monday, 05'th May 2025
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.09 per share a year ago.
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
07:00am, Monday, 05'th May 2025
Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY ® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI ® 1Q
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
07:00am, Thursday, 01'st May 2025
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
11:06am, Monday, 28'th Apr 2025
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 22'nd Apr 2025
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a
Kuehn Law Encourages Investors of Five Below, Inc. to Contact Law Firm
02:03pm, Wednesday, 16'th Apr 2025
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Five Below, Inc. (NASDAQ: FIVE) breached the
